DIROXIMEL FUMARATE TO REDUCE PERIHAEMATOMAL OEDEMA IN INTRACEREBRAL HAEMORRHAGE: DOUBLE BLIND RANDOMIZED CLINICAL TRIAL

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 192 participants.

Also called NCT07275515

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 192 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07275515
  • EU CT 2025-522687-33-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07275515. Randomized; quadruple masking; primary purpose treatment. Start 2026-05-19 (actual); primary completion 2029-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
DIROXIMEL FUMARATE TO REDUCE PERIHAEMATOMAL OEDEMA IN INTRACEREBRAL HAEMORRHAGE: DOUBLE BLIND RANDOMIZED CLINICAL TRIAL
Acronym
DARLENE
Condition
Stroke
Intervention (Drug)
DRF
Intervention (Drug)
Placebo
Lead sponsor
University Hospital, Lille (class: other)
Collaborator
Ministère de la Santé (class: AMBIG)

Record details

Record id
cardio:ct-nct07275515
Content hash
318592d580a8195feb210e6541c1fb738cb0d7714ed0fba92bb6b85e219d5690